Purpose To report the clinical outcomes of adalimumab therapy in cases of birdshot chorioretinitis (BCR) with cystoid macular edema (CME) refractory to conventional immunotherapy. Methods This is a retrospective case series of three BCR patients treated with adalimumab for refractory CME. The main outcome measure was central subfield thickness (CST) on optical coherence tomography. Any patients treated with local steroids and/or receiving systemic steroids higher than 40 mg prednisolone daily during adalimumab therapy were excluded. Results At baseline, all patients were receiving systemic corticosteroids and two second-line immunosuppressive agents. The mean duration of treatment with adalimumab was 31.2 months (range 17.2-52). The mean CST was 327 ± 112.7 lm (mean ± SD) at baseline and 256.2 ± 39.7 lm at 6 months and 235.5 ± 32.5 lm at 12 months. Adalimumab permitted cessation or reduction in the daily dose of oral prednisolone plus withdrawal of a second-line agent in all patients. Conclusions In these patients, adalimumab was effective in the treatment of refractory CME.
Introduction
Birdshot chorioretinopathy (BCR) is a rare posterior uveitis involving the choroid and retinal vasculature that is strongly associated with the human leukocyte antigen (HLA)-A29 [1] . It is an isolated ocular disorder characterized by the presence of multiple choroidal hypopigmented inflammatory lesions. The diagnosis remains clinical, and the natural history is typically chronic resulting in a progressive decline in retinal function on visual field and electroretinogram testing [2] . Chronic cystoid macular edema (CME) is the predominant cause of central vision loss [3] [4] [5] . Early and aggressive immunosuppressive treatment is recommended to preserve vision [6, 7] , with the standard of care being systemic corticosteroids plus conventional second-line immunosuppressive drugs such as anti-proliferative agents and T cell inhibitors. In refractory cases, biologic agents such as intravenous immunoglobulins [8] , daclizumab [9] , tocilizumab [10] and infliximab [11] have all been tried with varying success.
The recent VISUAL trials have provided level 1 evidence supporting the clinical efficacy of adalimumab, a humanized monoclonal antibody targeted against tumor necrosis (TNF) alpha, in reducing the frequency of inflammatory relapse for uveitis patients with a diverse range of uveitic diagnoses [12, 13] . This included BCR, but a subgroup analysis was not reported and the inclusion criteria were not limited to refractory disease. Specific outcomes for BCR including electrodiagnostic tests (EDTs) were also not measured. In usual clinical practice, funding for high cost interventions such as adalimumab in rare conditions is often limited to patients who fail to achieve disease remission with the standard of care, and in this context, retrospective case series remain valuable in guiding treatment decisions. We are therefore reporting the clinical outcome of adalimumab therapy in cases of BCR with refractory CME.
Methods
The medical records of all patients with CME associated with BCR treated with adalimumab in our center were reviewed. The diagnosis of BCR was based on the criteria published by Levinson et al. [14] and the presence of a normal chest X-ray, normal angiotensin-converting enzyme levels, negative syphilis serology and negative quantiFERON test. All patients received adalimumab 40 mg subcutaneously every 2 weeks. Any patients that received local steroid therapy (intravitreal or periocular) and/or systemic corticosteroid higher than prednisolone 40 mg daily during adalimumab treatment were excluded. Data retrieved included age, gender, time since diagnosis and systemic immunosuppressive therapy at the start of adalimumab treatment. The best-corrected visual acuity (BCVA), central subfoveal thickness (CST) determined by optical coherence tomography (OCT) (3D OCT-2000, Topcon Corp., Tokyo, Japan) and changes in immunosuppressive therapy regime were recorded for the duration of adalimumab therapy. The main outcome measure was the effect on CST. Wider retinal function was evaluated by analysis of serial EDTs (Espion E2 system, Diagnosys LLC, Cambridge, UK) performed before and during adalimumab treatment.
All the quantitative variables were expressed as mean ± standard deviation (SD) unless otherwise specified.
Results
Three Caucasian patients with bilateral BCR and CME refractory to conventional systemic immunosuppressive therapy were included in the study. All the patients were HLA-A29 positive. Two patients were female. The mean age at diagnosis of BCR was 49.9 ± 5.2 (mean ± SD) years (range 46.6-55.9). The mean age at the time of starting adalimumab was 52.9 ± 6.1 (mean ± SD) years (range 47.7-59.6), with a mean time from diagnosis to initiation of adalimumab of 3.0 ± 1.6 years (mean ± SD) (range 1.2-4.1). Prior to adalimumab treatment, each patient received oral prednisone (all C10 mg/day) and two second-line immunosuppressive agents (Table 1) . None had previously received treatment with a biologic agent. The mean duration of adalimumab treatment was 31.2 months (range 24.4-52). Table 1 summarizes the demographic data, systemic treatment and visual acuity at baseline and at the end of follow-up.
OCT central subfoveal thickness Figure 1 shows the evolution of the CST for each patient from the start of immunosuppressive therapy to the end of follow-up. Key therapeutic changes are highlighted. The mean CST for all patients (6 eyes) was 327 ± 112.7 lm (mean ± SD) at baseline and 256.2 ± 39.7 lm (mean ± SD) and 235.5 ± 32.5 lm (mean ± SD) after 6 and 12 months of adalimumab therapy (Fig. 2) .
Visual acuity BCVA improved in four eyes (three patients) and remained stable in two eyes (two patients) from introduction of adalimumab to the end of follow-up (Table 1) .
Electrodiagnostic test (EDTs)
Serial ISCEV standard dark-adapted (DA) 3.0 (combined rod cone) and light-adapted (LA) 3.0 flicker (30 Hz) ERGs were performed. Amplitudes of both A and B waves of the DA 3.0 response, 30-Hz flicker and latency of the 30-Hz flicker were analyzed over time, and the average pre-and post-drug measurements were compared. There was an improvement in the amplitude of A and B waves of the DA 3.0 response in four of the six eyes post-treatment, an improvement in the amplitude of the 30-Hz flicker in four of the six eyes and an improvement in the latency in five of the six eyes post-treatment. Table 2 summarizes the results for each patient and each parameter pre-and post-treatment.
Changes in inflammation score
All the patients included had posterior uveitis as the main clinical feature. The baseline vitreous haze score was 0?, and the baseline anterior chamber was 0? (as per standardization of uveitis nomenclature (SUN) guidelines) [15] in all the cases. No significant changes in this grading occurred after treatment with adalimumab was started.
Changes to systemic treatment
At the end of follow-up, adequate control of inflammation and CME permitted reduction of the systemic immunosuppressive therapy regimes in all three patients. Oral corticosteroid treatment was withdrawn in one patient and reduced in the other two patients to B7.5 mg daily (Fig. 1) .
Discussion
There is a strong and increasing evidence base in favor of anti-TNF alpha therapies for the treatment of uveitis, exemplified by the recent VISUAL trials [12, 13] . However, a dearth of disease-specific data remains. For refractory BCR, a previous retrospective case series of patients treated with infliximab (a non-humanized, chimeric anti-TNF alpha monoclonal antibody) concluded that this was effective in controlling disease in 89% of cases at 12 months [11] . This included a good response in seven eyes in five patients with bilateral refractory BCR-associated CME. Our results for adalimumab treatment endorse this observation, which suggests that rather than being drug-specific effect, treatment benefit is attributable to the class of anti-TNF alpha therapies as a whole. Furthermore, in all three cases, adalimumab led to an improvement in at least one electrodiagnostic parameter, a reduction in concomitant oral prednisone therapy and the number of second-line immunosuppressive treatments used. It is important to acknowledge limitations of using case series such as this as the basis of clinical practice, in particular with regard to the biases introduced by variable duration of follow-up and a small sample size. However, these limited data support the use of adalimumab in treating CME associated with BCR refractory to treatment with [10 mg prednisone daily and two conventional second-line immunosuppressive agents. 
